KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Invested Capital (2016 - 2026)

Emergent BioSolutions has reported Invested Capital over the past 17 years, most recently at $1.1 billion for Q1 2026.

  • For Q1 2026, Invested Capital fell 11.17% year-over-year to $1.1 billion; the TTM value through Mar 2026 reached $1.1 billion, down 11.17%, while the annual FY2025 figure was $1.1 billion, 5.96% down from the prior year.
  • Invested Capital for Q1 2026 was $1.1 billion at Emergent BioSolutions, roughly flat from $1.1 billion in the prior quarter.
  • Over five years, Invested Capital peaked at $2.8 billion in Q4 2022 and troughed at $1.1 billion in Q4 2025.
  • A 5-year average of $1.7 billion and a median of $1.5 billion in 2023 define the central range for Invested Capital.
  • Biggest five-year swings in Invested Capital: increased 13.83% in 2022 and later tumbled 45.83% in 2023.
  • Year by year, Invested Capital stood at $2.8 billion in 2022, then tumbled by 45.83% to $1.5 billion in 2023, then fell by 22.07% to $1.2 billion in 2024, then dropped by 5.96% to $1.1 billion in 2025, then rose by 0.04% to $1.1 billion in 2026.
  • Business Quant data shows Invested Capital for EBS at $1.1 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.3 billion in Q3 2025.